Volume : 10, Issue : 02, February – 2023
Title:
10.FORMULATION DEVELOPMENT OF IRBESARTAN (POORLY WATER-SOLUBLE DRUG) FOR ORAL ADMINISTRATION
Authors :
Gaddam Shalini, Zeenath Ruhy
Abstract :
The aim of the present study is to increase the solubility of poorly water soluble drug Irbesartan by using surfactants and formulating into immediate release tablets by using super disintegrants. Surfactants such as sodium lauryl sulfate, polysorbate, and poloxamer 800 are used for increasing the solubility of drug in water by micellisation technique. Super disintegrant such as croscarmellose sodium was used for fast disintegration. Physical properties for granules such as Bulk density, Tapped density, Hausners ratio, % compressibility, % LOD and physical characteristics for Irbesartan IR tablets such as weight variation, friability, hardness, thickness, disintegration, in-vitro dissolution were studied. % cumulative drug release of formulation T3 (having 2% Tween 80) matched with the innovator product Avapro and the similarity factor between innovator and T3 was 97.
Keywords: Formulation, Development, Irbesartan (Poorly Water-Soluble Drug), Oral Administration
Cite This Article:
Please cite this article in press Gaddam Shalini et al, Formulation Development Of Irbesartan (Poorly Water-Soluble Drug) For Oral Administration ., Indo Am. J. P. Sci, 2023; 10 (02).
Number of Downloads : 10
References:
2. Aguiar AJ., Zelmer AJ., Kinkel AW. Deagglomeration behavior of relatively insoluble benzoic acid and its sodium salt, J. Pharm. Sci, 56,1979, 1243–1252.
3. Kapsi SG., Ayres JW. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability, Int. J. Pharm. 229, 2001, 193–203.
4. Finholt P., Solvang S. Dissolution kinetics of drugs in human gastric juice the role of surface tension, J. Pharm. Sci, 57, 1968, 1322–1326.
5. Gursoy RN., Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drug, Biomed. Pharmacother, 58, 2004, 173–182.
6. Pouleur HG. Clinical overview of Irbesartan: A new angiotensin II receptor antagonist. Ame. J. Hypertens.10,1997,318–324.
7. Chawla G., Bansal AK. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Euro. J Pharm Sci. 32,2007,45–57.
8. Hirlekar R., Kadam V. Preformulation Study of the inclusion complex irbesartan-β- cyclodextrin. AAPS Pharm SciTech, 2009; 10(1). doi: 10, 1208/s12249-009-9206-5.
9. Kapsi SG., Ayres JW. Processing factors in developmentnof solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int. J. Pharm.,229, 2001,193-203.
10. Sharma DK., Joshi SB. Solubility enhancement strategies for poorly water-soluble drugs in solid dispersions: A review; Asian J. Pharm.,1, 2007,9-19.
11. Spireas SS., Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int. J. Pharm., 166, 1998, 177-188.
12. Spireas SS., Liquisolid system and method of preparing same. United State Patent no 6096337. 2000, August 1st.